(CNC) Centene - Ratings and Ratios
Medicaid Plans, Medicare Products, Marketplace Coverage, Pharmacy Services
CNC EPS (Earnings per Share)
CNC Revenue
Description: CNC Centene
Centene Corporation (NYSE:CNC) is a U.S.-based managed-care provider that focuses on delivering health-care coverage and services to under-insured, uninsured, and commercially insured populations through four primary segments: Medicaid, Medicare, Commercial, and Other.
The Medicaid segment, the company’s largest revenue driver, administers a range of public programs-including Temporary Assistance for Needy Families (TANF), Medicaid expansion, and Children’s Health Insurance Program (CHIP)-as well as long-term services, foster-care placements, and dual-eligible Medicare-Medicaid plans. The Medicare segment offers special-needs plans, supplemental coverage, and prescription-drug benefits, while the Commercial segment sells marketplace products to individuals and groups of varying sizes. The “Other” segment encompasses clinical operations (primary and specialty care, hospitals, behavioral health), pharmacy services, and ancillary offerings such as vision, dental, and corporate management solutions.
Key performance indicators from the most recent fiscal year (2023) show revenue of $138.5 billion, a net income of $2.5 billion, and an operating margin of roughly 3.5 %. Medicaid enrollment rose ~5 % YoY to over 20 million members, reflecting continued demographic aging and state-level Medicaid expansion. A primary sector driver is federal and state policy on Medicaid funding and ACA marketplace subsidies, which directly influence capitation rates and enrollment growth. Additionally, rising prescription-drug costs and the shift toward value-based care contracts are pressuring margins across all segments.
For a deeper, data-driven look at CNC’s valuation assumptions and scenario analysis, you may find ValueRay’s analytical tools worth exploring.
CNC Stock Overview
| Market Cap in USD | 17,322m |
| Sub-Industry | Managed Health Care |
| IPO / Inception | 2001-12-13 |
CNC Stock Ratings
| Growth Rating | -72.0% |
| Fundamental | 66.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -49.1% |
| Analyst Rating | 3.89 of 5 |
CNC Dividends
Currently no dividends paidCNC Growth Ratios
| Growth Correlation 3m | 93.7% |
| Growth Correlation 12m | -75.3% |
| Growth Correlation 5y | -33.3% |
| CAGR 5y | -25.03% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.35 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.99 |
| Sharpe Ratio 12m | 0.32 |
| Alpha | -51.56 |
| Beta | 0.476 |
| Volatility | 32.12% |
| Current Volume | 7289.7k |
| Average Volume 20d | 8494.7k |
| Stop Loss | 34.3 (-4.8%) |
| Signal | 0.22 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (2.05b TTM) > 0 and > 6% of Revenue (6% = 10.69b TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -1.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2.02% (prev 3.60%; Δ -1.58pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 1.73b <= Net Income 2.05b (YES >=105%, WARN >=100%) |
| Net Debt (3.06b) to EBITDA (4.39b) ratio: 0.70 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.10 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (493.5m) change vs 12m ago -7.01% (target <= -2.0% for YES) |
| Gross Margin 8.93% (prev 10.96%; Δ -2.03pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 210.2% (prev 189.7%; Δ 20.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.13 (EBITDA TTM 4.39b / Interest Expense TTM 688.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.46
| (A) 0.04 = (Total Current Assets 40.39b - Total Current Liabilities 36.79b) / Total Assets 86.39b |
| (B) 0.19 = Retained Earnings (Balance) 16.41b / Total Assets 86.39b |
| (C) 0.04 = EBIT TTM 3.53b / Avg Total Assets 84.77b |
| (D) 0.27 = Book Value of Equity 16.18b / Total Liabilities 58.89b |
| Total Rating: 1.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.40
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 5.30% = 2.65 |
| 3. FCF Margin 0.61% = 0.15 |
| 4. Debt/Equity 0.64 = 2.30 |
| 5. Debt/Ebitda 0.70 = 2.13 |
| 6. ROIC - WACC (= 3.52)% = 4.39 |
| 7. RoE 7.53% = 0.63 |
| 8. Rev. Trend 91.53% = 6.87 |
| 9. EPS Trend -44.34% = -2.22 |
What is the price of CNC shares?
Over the past week, the price has changed by +0.64%, over one month by +10.15%, over three months by +29.15% and over the past year by -41.01%.
Is Centene a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CNC is around 32.52 USD . This means that CNC is currently overvalued and has a potential downside of -9.72%.
Is CNC a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CNC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 36 | -0.1% |
| Analysts Target Price | 36 | -0.1% |
| ValueRay Target Price | 34.9 | -3.1% |
Last update: 2025-10-20 03:48
CNC Fundamental Data Overview
P/E Trailing = 8.5607
P/E Forward = 10.3734
P/S = 0.1085
P/B = 0.6598
P/EG = 1.0748
Beta = 0.476
Revenue TTM = 178.19b USD
EBIT TTM = 3.53b USD
EBITDA TTM = 4.39b USD
Long Term Debt = 17.55b USD (from longTermDebt, last quarter)
Short Term Debt = 25.0m USD (from shortTermDebt, last quarter)
Debt = 17.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.06b USD (from netDebt column, last quarter)
Enterprise Value = 20.39b USD (17.32b + Debt 17.58b - CCE 14.51b)
Interest Coverage Ratio = 5.13 (Ebit TTM 3.53b / Interest Expense TTM 688.0m)
FCF Yield = 5.30% (FCF TTM 1.08b / Enterprise Value 20.39b)
FCF Margin = 0.61% (FCF TTM 1.08b / Revenue TTM 178.19b)
Net Margin = 1.15% (Net Income TTM 2.05b / Revenue TTM 178.19b)
Gross Margin = 8.93% ((Revenue TTM 178.19b - Cost of Revenue TTM 162.29b) / Revenue TTM)
Gross Margin QoQ = 6.05% (prev 11.16%)
Tobins Q-Ratio = 0.24 (Enterprise Value 20.39b / Total Assets 86.39b)
Interest Expense / Debt = 0.97% (Interest Expense 170.0m / Debt 17.58b)
Taxrate = -0.78% (negative due to tax credits) (2.00m / -257.0m)
NOPAT = 3.56b (EBIT 3.53b * (1 - -0.78%)) [negative tax rate / tax credits]
Current Ratio = 1.10 (Total Current Assets 40.39b / Total Current Liabilities 36.79b)
Debt / Equity = 0.64 (Debt 17.58b / totalStockholderEquity, last quarter 27.41b)
Debt / EBITDA = 0.70 (Net Debt 3.06b / EBITDA 4.39b)
Debt / FCF = 2.84 (Net Debt 3.06b / FCF TTM 1.08b)
Total Stockholder Equity = 27.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.38% (Net Income 2.05b / Total Assets 86.39b)
RoE = 7.53% (Net Income TTM 2.05b / Total Stockholder Equity 27.26b)
RoCE = 7.88% (EBIT 3.53b / Capital Employed (Equity 27.26b + L.T.Debt 17.55b))
RoIC = 7.86% (NOPAT 3.56b / Invested Capital 45.27b)
WACC = 4.35% (E(17.32b)/V(34.90b) * Re(7.77%) + D(17.58b)/V(34.90b) * Rd(0.97%) * (1-Tc(-0.01)))
Discount Rate = 7.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -4.19%
[DCF Debug] Terminal Value 71.95% ; FCFE base≈1.55b ; Y1≈1.09b ; Y5≈570.1m
Fair Price DCF = 22.34 (DCF Value 10.97b / Shares Outstanding 491.1m; 5y FCF grow -34.97% → 3.0% )
EPS Correlation: -44.34 | EPS CAGR: -25.47% | SUE: 0.52 | # QB: 0
Revenue Correlation: 91.53 | Revenue CAGR: 11.80% | SUE: 3.94 | # QB: 10
Additional Sources for CNC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle